10.36

3.08% 0.31

After Hours: 10.36

Enanta Pharmaceuticals Inc (ENTA)

Overview News Price History Option Chain Financials Discussions Forecast

Enanta Pharmaceuticals Inc stock is traded at $10.36, with a volume of 164.94K. It is up +3.08% in the last 24 hours and down -19.57% over the past month. Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Previous Close:

$10.05

Open:

$9.96

24h Volume:

164.94K

Relative Volume:

1.02

Market Cap:

$212.95M

Revenue:

$73.62M

Net Income/Loss:

$-138.24M

P/E Ratio:

-1.6412

EPS:

-6.3125

Net Cash Flow:

$-99.19M

1W Performance:

-5.82%

1M Performance:

-19.57%

6M Performance:

-40.66%

1Y Performance:

-7.25%

1-Day Range:

$9.895

$10.43

1-Week Range:

$9.895

$11.21

52-Week Range:

$8.08

$17.80

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name

Enanta Pharmaceuticals Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

617 607 0800

Address

500 ARSENAL STREET, WATERTOWN, MA

Employee

145

Twitter

@EnantaPharma

Next Earnings Date

2024-08-05

Latest SEC Filings

ENTA's Discussions on Twitter

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-22	Initiated	H.C. Wainwright	Buy
Jul-06-22	Upgrade	Evercore ISI	In-line → Outperform
Jun-01-22	Upgrade	Evercore ISI	Underperform → In-line
Oct-07-21	Initiated	Jefferies	Buy
Sep-09-21	Initiated	SVB Leerink	Mkt Perform
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Nov-24-20	Initiated	Evercore ISI	Underperform
Aug-28-20	Resumed	ROTH Capital	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-27-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Mar-17-20	Upgrade	Robert W. Baird	Neutral → Outperform
Nov-22-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-26-19	Downgrade	JP Morgan	Neutral → Underweight
May-24-19	Initiated	Wolfe Research	Outperform
Apr-23-19	Upgrade	Berenberg	Hold → Buy
Dec-13-18	Initiated	Berenberg	Hold
Jun-06-18	Initiated	ROTH Capital	Buy
Feb-08-18	Downgrade	JP Morgan	Overweight → Neutral
Jan-02-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-21-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Jul-11-17	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Apr-28-16	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-09-16	Reiterated	Barclays	Underweight
Oct-23-15	Downgrade	Barclays	Equal Weight → Underweight
Oct-23-15	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform

View All

Enanta Pharmaceuticals Inc Stock (ENTA) Latest News

Sep 28, 2024

Enanta shares hold as Baird affirms target on new data By Investing.com - Investing.com Canada

Sep 28, 2024

Sep 27, 2024

Enanta’s Phase II Challenge Data Position A Second Potential RSV Therapy - Scrip

Sep 27, 2024

Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Reiterated by JMP Securities - MarketBeat

Sep 27, 2024

Rhumbline Advisers Increases Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Sep 27, 2024

Enanta’s next RSV pill raises ‘high bar set by zelicapavir’ - The Pharma Letter

Sep 27, 2024

Sep 26, 2024

Enanta reports promising results for RSV drug EDP-323 - Investing.com

Sep 26, 2024

Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study - Benzinga

Sep 26, 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Armistice Capital LLC - MarketBeat

Sep 26, 2024

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) - StockTitan

Sep 26, 2024

Sep 22, 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Bank of New York Mellon Corp - Defense World

Sep 22, 2024

Sep 20, 2024